
Opinion|Videos|July 12, 2024
Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC
Alan Chin, PharmD, BCOP, examines the PALOMA-3 trial's influence on the treatment of EGFR-mutated metastatic NSCLC and explores the evolving role of antibody-drug conjugates (ADCs) in the therapeutic landscape of EGFR-mutated NSCLC.
Advertisement
Episodes in this series

- How might the advent of subcutaneous amivantamab, currently being studied in the
PALOMA-3 trial, impact the treatment of EGFR-mutated metastatic NSCLC? What opportunities or challenges might this impose? - How do you see the role of antibody-drug conjugates (ADCs) evolving in the treatment landscape of EGFR-mutated NSCLC, and are there any in the pipeline that you are particularly excited about?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
2
FDA Approves First Drug for Pediatrics With Irritable Bowel Syndrome With Constipation
3
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
4
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
5













































































































































































































